Ep170: David Schenkein on Investing in the Future of Biotech

Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.

Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.

Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.

Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.

David Schenkein, general partner at GV, on investing in the future of biotech.

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.

Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.

Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.

Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.